Study protocol for FASTRAK: a randomised controlled trial evaluating the cost impact and effectiveness of FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer

Pierre Nahon,Maxime Ronot,Olivier Sutter,Pierre-André Natella,Samia Baloul,Isabelle Durand-Zaleski,Etienne Audureau

DOI: https://doi.org/10.1136/bmjopen-2023-083701

IF: 3.006

2024-02-18

BMJ Open

Abstract:Introduction The surveillance of hepatocellular carcinoma (HCC) using semi-annual liver ultrasound (US) is justified in patients with cirrhosis. In this context, US has a low sensitivity (<30%) for the detection of HCC at the very early stage (ie, Barcelona clinic liver cancer (BCLC) 0, uninodular tumour 3% per year) could increase the rates of patients with a tumour detected at an early stage accessible to curative-intent treatment, and demonstrate its cost-effectiveness in this population. Methods and analysis The FASTRAK trial is a multicentre, randomised controlled trial with two parallel arms, aiming for superiority and conducted on patients at high risk for HCC (yearly HCC incidence >3%). Randomisation will be conducted on an individual basis with a centralised approach and stratification by centre. After inclusion in the trial, each patient will be randomly assigned to the experimental group (semi-annual US and AMRI) or the control group (semi-annual US alone). The main objective is to assess the cost/quality-adjusted life year and cost/patient detected with a BCLC 0 HCC in both arms. A total of 944 patients will be recruited in 37 tertiary French centres during a 36-month period and will be followed-up during 36 months. Ethics and dissemination The FASTRAK trial received ethical approval on 4 April 2022. Results will be disseminated via publication in peer-reviewed journals as well as presentation at international conferences. Trial registration number Clinical trial number (ClinicaTrials.gov) NCT05095714.

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate whether semi - annual screening using fast magnetic resonance imaging (FAST - MRI, abbreviated as AMRI) in patients at high risk of hepatocellular carcinoma (HCC) is more cost - effective than the traditional semi - annual liver ultrasound (US), and whether it can improve the detection rate of HCC in the early stage (i.e., BCLC stage 0). Specifically: 1. **Problem Background**: - Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth most deadly cancer worldwide. - In 85% of cases, HCC occurs in the context of cirrhosis, mainly caused by excessive alcohol consumption, metabolic syndrome, or hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. - Currently, semi - annual ultrasound examinations are recommended for cirrhotic patients to detect early HCC, but the sensitivity of ultrasound examinations to very early - stage HCC (such as a single tumor < 2cm) is low (< 30%). 2. **Research Objectives**: - **Primary Objective**: To evaluate the differences in cost/quality - adjusted life years (QALY) and cost per detected BCLC stage 0 HCC patient between using semi - annual liver ultrasound and AMRI and using only semi - annual liver ultrasound in high - risk HCC patients. - **Secondary Objectives**: To compare the proportion of very early - stage HCC detected under the two screening strategies; to confirm the metrological characteristics of AMRI for non - invasive detection of very early - stage HCC < 2cm; to evaluate the mode and determinants of initial curative treatment; to evaluate overall survival rate and recurrence - free survival rate; to describe the acceptance and compliance of patients to the screening program and their determinants. 3. **Hypotheses**: - The study hypothesizes that AMRI, as a screening tool, can increase the detection rate of very early - stage HCC in high - risk HCC patients, thereby increasing the chances of being assigned to curative treatment and improving survival rate, while demonstrating its cost - effectiveness in this population. Through this randomized controlled trial (FASTRAK), researchers hope to find a more effective method for early detection of HCC to improve patient survival rate and optimize the use of medical resources.

Study protocol for FASTRAK: a randomised controlled trial evaluating the cost impact and effectiveness of FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer

Hepatic Resection Versus TILA-TACE in the Treatment of Resectable Hepatocellular Carcinoma: Study Protocol for a Randomized Controlled Trial

Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial

Prospective Study of Non-Contrast, Abbreviated MRI for Hepatocellular Carcinoma Surveillance in Patients with Suboptimal Hepatic Visualisation on Ultrasound

Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis

Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial

Study protocol: HepaT1ca - an observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures

Impact of a health literacy intervention combining general practitioner training and a consumer facing intervention to improve colorectal cancer screening in underserved areas: protocol for a multicentric cluster randomized controlled trial

Breast cancer: a randomized controlled trial assessing the effect of a decision aid on mammography screening uptake: study protocol

Integrating artificial intelligence into lung cancer screening: a randomised controlled trial protocol

Colorectal Cancer Screening Decision Based on Predicted Risk: Protocol for a Pilot Randomized Controlled Trial

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)

Diagnostic accuracy of serological and imaging tests used in surveillance for hepatocellular carcinoma in adults with cirrhosis: a systematic review protocol

FIT for purpose: study protocol for a randomized controlled trial to personalize surveillance colonoscopy for individuals at elevated risk of colorectal cancer

Protocol for open-label, randomised, controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer (SARONG trial).

Prospective cohort for early detection of liver cancer (Pearl): a study protocol

Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.

Lung CAncer SCreening in French women using low-dose CT and Artificial intelligence for DEtection: the CASCADE study protocol

Study protocol for a single-centre non-inferior randomised controlled trial on a novel three-dimensional matrix positioning-based cognitive fusion-targeted biopsy and software-based fusion-targeted biopsy for the detection rate of clinically significant prostate cancer in men without a prior biopsy

Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC